Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Bicycle Therapeutics (NASDAQ: BCYC) announced that its Compensation Committee granted inducement awards to thirteen new employees on December 2, 2024. The awards consist of non-qualified share options to purchase 62,400 ordinary shares at an exercise price of $20.40 per share. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months. These grants were made under the company's 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Bicycle Therapeutics (NASDAQ: BCYC) ha annunciato che il suo Comitato per le Compensazioni ha concesso premi di indennità a tredici nuovi dipendenti il 2 dicembre 2024. I premi consistono in opzioni su azioni non qualificate per acquistare 62.400 azioni ordinarie a un prezzo di esercizio di 20,40 $ per azione. Le opzioni matureranno in quattro anni, con il 25% che matura dopo un anno e il saldo rimanente che matura mensilmente per 36 mesi. Questi premi sono stati concessi secondo il piano di indennità 2024 dell'azienda, in conformità con la Regola 5635(c)(4) delle quotazioni Nasdaq.
Bicycle Therapeutics (NASDAQ: BCYC) anunció que su Comité de Compensación otorgó premios de inducción a trece nuevos empleados el 2 de diciembre de 2024. Los premios consisten en opciones de acciones no calificadas para comprar 62,400 acciones ordinarias a un precio de ejercicio de $20.40 por acción. Las opciones adquirirán vigencia durante cuatro años, con el 25% adquiriendo vigencia después de un año y el saldo restante adquiriendo vigencia mensualmente durante 36 meses. Estas concesiones se realizaron bajo el Plan de Inducción 2024 de la empresa, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Bicycle Therapeutics (NASDAQ: BCYC)는 2024년 12월 2일 보상위원회가 새로 입사한 13명의 직원에게 유인상금을 수여했다고 발표했습니다. 상금은 62,400주의 보통주를 주당 20.40달러의 행사 가격으로 구매할 수 있는 비자격 주식 옵션으로 구성됩니다. 이 옵션은 4년에 걸쳐 만료되며, 첫 해가 지나면 25%가 만료되고 나머지 잔액은 36개월 동안 매월 만료됩니다. 이러한 보상은 나스닥 상장 규칙 5635(c)(4)에 따라 회사의 2024년 유인 계획에 따라 이루어졌습니다.
Bicycle Therapeutics (NASDAQ: BCYC) a annoncé que son Comité de Compensation a accordé des primes d'incitation à treize nouveaux employés le 2 décembre 2024. Les primes consistent en options d'achat d'actions non qualifiées pour acquérir 62 400 actions ordinaires à un prix d'exercice de 20,40 $ par action. Les options acquériront des droits sur une période de quatre ans, avec 25 % devenant acquises après un an et le solde restant acquérant des droits mensuellement sur 36 mois. Ces attributions ont été faites dans le cadre du Plan d'Incitation 2024 de l'entreprise conformément à la Règle de Cotation 5635(c)(4) de Nasdaq.
Bicycle Therapeutics (NASDAQ: BCYC) gab bekannt, dass sein Vergütungsausschuss am 2. Dezember 2024 dreizehn neuen Mitarbeitern Anreizvergaben gewährt hat. Die Vergaben bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von 62.400 Stammaktien zu einem Ausübungspreis von 20,40 $ pro Aktie. Die Optionen werden über einen Zeitraum von vier Jahren auslaufen, wobei 25% nach einem Jahr und der verbleibende Betrag monatlich über 36 Monate fällig wird. Diese Vergaben wurden im Rahmen des Induktionsplans 2024 des Unternehmens gemäß der Nasdaq-Listing-Regel 5635(c)(4) vorgenommen.
- Company is expanding workforce with 13 new hires, indicating business growth
- Share dilution through issuance of 62,400 new stock options
Each option has an exercise price equal to
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin (formerly BT8009), a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology.
Bicycle Therapeutics is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241202862254/en/
Investors:
Stephanie Yao
SVP, Investor Relations and Corporate Communications
stephanie.yao@bicycletx.com
857-523-8544
Matthew DeYoung
Argot Partners
ir@bicycletx.com
212-600-1902
Media:
Jim O’Connell
Weber Shandwick
media@bicycletx.com
312-988-2343
Source: Bicycle Therapeutics plc
FAQ
How many shares were granted in Bicycle Therapeutics (BCYC) December 2024 inducement awards?
What is the exercise price for BCYC's December 2024 inducement stock options?
What is the vesting schedule for BCYC's December 2024 inducement grants?
